We are proud to be included in CB Insights’ Digital Health 150 — an annual ranking of the most promising startups redefining healthcare — for the second year in a row.
The Digital Health 150 is a list of the 150 most innovative digital health startups and private companies worldwide. Verana earned a spot within the real-world evidence (RWE) category under drug research and development.
We were selected by the CB Insights’ research team, which evaluated nearly 8,000 startups to select the final 150 companies. The selection process considered a range of factors, including business relations, investor profile, news sentiment analysis, market potential, competitive landscape, team strength, and tech novelty.
CB Insights’ CEO Anand Sanwal will showcase the final Digital Health 150 during the Future of Health conference (Sept 23-25) — a virtual gathering of top executives across some of the largest healthcare institutions, startups, and investment firms.
The full Digital Health 150 rankings report is available here.